Rosacea Market

Rosacea Market

  • Home
  • Healthcare
  • Rosacea Market
  • |Published Month : January, 2023
  • |No. of Pages : 135

Rosacea Market Overview

The global Rosacea market size is estimated to reach $3.3 Billion in 2030 from $1.96 Billion in 2020, at a CAGR of 5.47% between 2020 and 2030. The demand for Rosacea from emerging Asian and Latin American countries is poised to increasing rapidly, in particular, from second half of forecast period, following the increasing awareness rapid penetration of topical antibiotics. Increasing prevalence of the condition and growing awareness and affordability driven by launch of new drug candidates and strong pipeline are poised to drive the market.

Rosacea is a chronic inflammatory skin disease with symptoms such as deep facial redness, spider veins (telangiectasia) and acne-like inflammatory lesions (papules and pustules). It may create psychosocial burdens, such as embarrassment, anxiety and low self-esteem that may adversely affect quality of life.

Rosacea is categorized into four sub-types:

  • Erythematotelangiectatic Rosacea
  • Papulopustular Rosacea
  • Phymatous Rosacea
  • Ocular Rosacea


Some of the major developments likely to impact the industry

  • Launch of Zilxi (minocycline topical foam, 1.5% in 2020)
  • Potential approval of Epsolay (VERED) in 2021
  • Impact of Awareness programs being conducted by companies to boost adherence
  • Continued expansion of Generics in developing markets


Rosacea Market Analysis, 2021

Growing awareness about rosacea, increasing prevalence of the condition, changing lifestyles coupled with awareness programs and absence of treatment for rosacea are encouraging companies to invest significantly in R&D to develop products to gain from the huge unmet demand. Companies like Sol-Gel Technologies, Biowest Therapeutics, Maruho Co., Ltd, Amgen, Alfasigma, Biomemtix, Timber Pharmaceuticals, and others are focusing on constantly assessing diverse mechanism of actions to identify potential treatment options.


Rosacea is a chronic, inflammatory and vascular disorder affecting the face. Onset is usually after age 30 and typically begins as flushing and subtle redness on the cheeks, nose, chin or forehead. The characteristic skin lesions (erythema, visible blood vessels, papules and pustules) appear on the face and with progression of the disease, the redness becomes more persistent, blood vessels become visible and pimples often appear. In addition, burning, stinging, dry skin, plaques and skin thickening are other symptoms observed in the condition.


Rosacea is one of the most common conditions treated by dermatologists but the etiology of the condition is unknown. A family history of the disease is a risk factor, as is the very light skin phototype (Celtic skin type). The condition may be triggered from consumption of alcohol, spicy food, and changes in weather, exposure to sun or hot showers. Stinging, burning, sensitivity of the skin and inability to tolerate cosmetics are also common in rosacea. The condition has a strong impact on quality of life and can be associated with depressive symptoms.


Strong pipeline is of one of the market drivers of Rosacea market. Companies are focusing on launching new products based on significant opportunities for strong product positioning, focused primarily on novel delivery and high efficacy. Millennial and population aged between 30 and 50 remain major target group. Further, companies in the US and Europe increasingly rely on prescribing behaviour as focused guide for HCP targeting. Comparative pricing to other branded products, and ensuring broad access are among the key strategies opted by companies with planned therapeutic pipeline candidates.


Currently, 7 major prescription drugs are marketed for rosacea. A significant volume of patients switches or discontinue Rosacea therapy after first diagnosis. Further, there is no known cure for rosacea and treatment is aimed at alleviating the disorder's symptoms. Current treatment methods include topical formulations of antimicrobials such as metronidazole, clindamycin and ivermectin, azelaic acid or retinoids. Further, oral and topical antibiotics are also widely prescribed.


Different oral and topical medications are prescribed by patients to treat the signs and symptoms associated with Rosacea. Physicians often suggest antibiotics and other drug types. They also prescribe medical therapy specifically to control the redness. Bumps and pimples often receive initial treatment with oral and topical therapy to bring the condition under immediate control, followed by long-term use of an anti-inflammatory therapy alone to maintain remission.


The global Rosacea market is valued at $1,960 million in 2020. Further, over the forecast period to 2030, the market is poised to register 5.47% growth (Compounded Annual Growth Rate- CAGR) to reach $3,340 million in 2030. The major factors shaping up the demand outlook include increasing incidences of disease, launch of generics, and possible approval of VERED. On the other hand, low penetration rate in developing markets, low awareness in these markets, unknown etiology of the condition, and inadequate diagnosis coupled with low adherence are main market challenges.


The report analyses the global Rosacea market across drug types, route of administration and geographies. The drug types analysed in the report include Alpha agonists, Antibiotics, Azelic acid and others. Among types, antibiotics remain the dominant drug type with 67.8% market share. This is largely driven by prescriptions of oral and topical antibiotics and presence of a large number of products in the category.


In terms of route of administration, the market is categorized into oral and topical. Of these, topical dominated the industry in terms of market size with 70.8% market share. This is largely due to the limited side effects of topical compounds and patient willingness to opt for topical gel and foams compared to oral medication. However, for Phymatous Rosacea and Ocular Rosacea conditions, oral medication is largely prescribed.


Awareness campaigns and expansion into new markets coupled with increasing diagnosis of the disease are the main market drivers for Rosacea in developed countries in North America, and Europe. Among regions, North America remained the global markets with the US being the world’s largest country for rosacea treatment. The region accounted for 64.2% of global market demand, followed by Europe (21.4%). On the other hand, Asia Pacific is the fastest growing geography, forecast to register 6.3% CAGR over the forecast period. The fastest growth in China, India, Brazil, Eastern Europe and other countries is driven by launch of new products and increased diagnosis in the second half of forecast period.


In terms of companies, the current market landscape is characterized by presence of a few players such as Galderma, Leo Pharma, Aclaris, and Vyne Therapeutics. In addition, companies marketing generics also have significant presence in the industry.


Rosacea Companies included in the research-


Allergan Plc.

Bayer Schering AG

Bausch Health Companies Inc.

Foamix Pharmaceuticals

Sol-Gel Technologies



Rosacea Market Trends- Combination topical therapy continues to gain traction

While single agent topical therapy is among the leading treatment option preferred for rosacea patients, an increasing trend towards use of combination topical therapy is being observed. Metronidazole and azelaic acid are among the most prescribed combination for the condition. Combination of topical and oral medication such as Ivermectin and oral doxycycline is also being assessed.

According to National Rosacea Society, fixed centrofacial erythema with periodic intensification, and phymatous changes remain the primary phenotypes while papules and pustules, flushing, telangiectasia, and ocular manifestations can also co-occur with the primary symptoms. Further, secondary signs and symptoms such as burning or stinging sensations, facial edema, and a dry appearance of central facial skin can be observed among patients.

As Rosacea is an evolving condition, physicians consider all clinical signs and symptoms of rosacea observed in an individual patient, identifying those signs and symptoms that change over time, and accordingly suggest the most suitable combination therapy applicable to target all rosacea symptoms.


Rosacea Market Drivers- Rosacea has Strong Unmet Demand

Rosacea presents significant unmet demand potential. As the approved drugs do not treat the condition but instead treats the symptoms and signs, there exists huge unmet market demand. Further, high rate of treatment discontinuation coupled with side effects of long term usage restrict market size growth.

Pharmaceutical companies and institutes are investing in developing drugs that has minimal side effects and has more efficacy such as extended release and microencapsulation technology.


Rosacea Market Report Segmentation-

  • Route of Administration
    • Oral
    • Topical
  • Drug Type
    • Alpha agonist
    • Antibiotics
    • Azelic acid
    • Others
  • Regions
    • North America
    • Europe
    • Asia Pacific
    • Middle East Africa
    • Latin America


Rosacea Pipeline Products (Phase and Phase 3)

  • Epsolay
  • Omiganan
  • Minocycline hydrochloride extended release
  • M1220
  • ACU-D1
  • Rifaximin
  • Erenumab
  • B244
  • BMX 010
  • HY01 (Hovine FarmaCienca)
  • Phenylbutyrate
  • BPX-04
  • AC-701

Marketed Drugs


Zilxi is the latest approved drug in the rosacea treatment market, with the minocycline drug being approved in 2020. It is the first new option for papulopustular rosacea in 5+ years and accordingly, presents significant demand potential. Marketed by Vyne Therapeutics Inc., the company made the drug available in pharmacies from October 2020 in the US. ZILXI (minocycline) topical foam, 1.5% is a topical form of the antibiotic minocycline. We anticipate the product to generate around $200 million by 2030 from initial sales of around $23 million in 2021. Though it will erode into the profits of competing products, we estimate the product to generate additional revenues to the industry with increased number of prescriptions.

1.1 List of Tables    6
1.2 List of Figures    7

2.1 Summary    8
2.1.1 Overview    8
2.1.2 Market Sales    10
2.1.3 Some of the major developments likely to impact the industry    11
2.2 Rosacea Industry Outlook, 2020 – 2030    12
2.3 Abbreviations    13

3.1 Market Segments - Types, Applications, and Countries    14
3.2 Report Guide    15
3.3 Research Methodology    16

4.1 GDP Outlook, 2020 – 2030    17
4.2 Population Outlook of Select Countries, 2020 – 2030    18

5.1 Industry Panorama    19
5.2 Major Companies    21
5.3 Market Trends    21
5.3.1 Impact of generics on global market size    22
5.3.2 Small companies offer potential investment and partnership opportunities    22
5.3.3 Combination topical therapy continues to gain traction    23
5.3.4 Rosacea has Strong Unmet Demand    23
5.3.5 Unknown etiology poses challenges for new product development    23
5.3.6 COVID-19 mask wearing worsens rosacea symptoms    24
5.3.7 Inadequate and difficult diagnosis challenges prevalence estimation in developing countries    24
5.3.8 Increase in disease prevalence    24
5.3.9 Off-label usage of drugs poses challenges    24
5.3.10 Increasing global Healthcare Expenditure worldwide is among the main market drivers    25
5.4 Leading Routes of Administration    26
5.4.1 Orals    27
5.4.2 Topical    28
5.5 Dominant Drug Classes    29
5.6 Regional Analysis    50

6.1 Post COVID Scenario    51
6.2 Pre COVID Scenario    52

7.1 Overview    53
7.1.1 The US dominates the North American Rosacea Market    54
7.2 Market Outlook by Country    55
7.2.1 The US    55
7.2.2 Other North America    56

8.1 Overview    57
8.1.1 Germany dominates the European Rosacea Market    58
8.2 Market Outlook by Country    59
8.2.1 Germany    59
8.2.2 United Kingdom    60
8.2.3 France    61
8.2.4 Spain    62
8.2.5 Italy    63
8.2.6 Other Europe    64

9.1 Overview    65
9.1.1 Japan dominates the Asia Pacific Rosacea Market    66
9.2 Market Outlook by Country    67
9.2.1 Japan    67
9.2.2 Other Asia Pacific    68

10.1 Overview    69

11.1 Vyne Therapeutics Inc    71
11.1.1 Overview    71
11.1.2 SWOT Analysis    72
11.2 Bausch Health Companies Inc    74
11.2.1 Overview    74
11.2.2 SWOT Analysis    76
11.2.3 Key Financials    77
11.3 Bayer Schering AG    80
11.3.1 Overview    80
11.3.2 SWOT Analysis    81
11.4 Allergan plc    83
11.4.1 Overview    83
11.4.2 SWOT Analysis    84
11.4.3 Key Financials    86
11.5 Sol-Gel Technologies    89
11.5.1 Overview    89
11.5.2 SWOT Analysis    90
11.5.3 Key Financials    92

12.    APPENDIX    95
12.1 About USD Analytics    95
12.2 Sources and Research Methodology    95
12.3 Copyright and Disclaimer    96

Sample Request